Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05130307
Other study ID # STUDY00013916
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date April 25, 2022
Est. completion date June 3, 2022

Study information

Verified date August 2022
Source University of Washington
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Using immersive virtual reality as a form of pain distraction during a brief "painful but tolerable" temperature.


Description:

This study will use Quantitative Sensory Testing (computer-controlled brief 10 second thermal pain stimuli) in healthy college students. The primary aim is to conduct a randomized, controlled study with healthy volunteers to explore whether interacting with virtual objects in VR via a highly immersive VR system makes VR significantly more effective/powerful compared to a less immersive VR system, vs. No VR, for reducing pain during quantitative sensory testing.


Recruitment information / eligibility

Status Completed
Enrollment 48
Est. completion date June 3, 2022
Est. primary completion date June 3, 2022
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Currently enrolled in a course at the University of Washington Psychology Dept., participating in the UW Psychology subject pool - Able to read, write and comprehend English - Able to complete study measures - Willing to follow our UW approved instructions - 18 years of age or older - Currently enrolled in a course at the University of Washington Psychology Dept., participating in the UW Psychology subject pool - Able to read, write and comprehend English - Able to complete study measures - Willing to follow our UW approved instructions - 18 years of age or older The following temporary inclusion/exclusion criterion will exist only as long as required or appropriate for COVID pandemic conditions. COVID-19 precautions. Vaccinated: Individuals are considered fully vaccinated 2 weeks after the second dose in a 2-dose series (e.g., Pfizer or Moderna) or 2 weeks after a single-dose vaccine (e.g., Johnson & Johnson). All students and researchers must wear masks at all times during the study, and participants and researchers must provide proof of full vaccination for full participation. If participants do not have proof of vaccination or are unvaccinated, they are still free to sign up for the study. They are invited. They can still earn the extra credit by reading educational materials, in person, during their scheduled time slot. If unvaccinated, or if they have no proof of vaccination, we request that students provide proof of a negative COVID-19 test from the UW test site at the faculty lounge, dated within 24 hours of the study (non-vaccinated students need a recent negative COVID-19 test from the UW before participating in the non-VR educational materials option. - Exclusion Criteria: - People how have already previously participated in this same study (e.g., last quarter) are not eligible to participate again. - Not enrolled in a course at the University of Washington Psychology Dept., participating in the UW Psychology subject pool - Not be able to read, write and comprehend English - Younger than 18 years of age. - Not capable of completing measures - Not capable of indicating pain intensity, - Not capable of filling out study measures, - Extreme susceptibility to motion sickness, - Seizure history, - Unusual sensitivity or lack of sensitivity to pain, - Sensitive skin, - Sensitive feet - Migraines - Diabetes The following temporary inclusion/exclusion criterion will exist only as long as required or appropriate for COVID pandemic conditions. COVID-19 precautions. Vaccinated: Individuals are considered fully vaccinated 2 weeks after the second dose in a 2-dose series (e.g., Pfizer or Moderna) or 2 weeks after a single-dose vaccine (e.g., Johnson & Johnson). All students and researchers must wear masks at all times during the study, and participants and researchers must provide proof of full vaccination for full participation. If participants do not have proof of vaccination or are unvaccinated, they are still free to sign up for the study. They are invited. They can still earn the extra credit by reading educational materials, in person, during their scheduled time slot. If unvaccinated, or if they have no proof of vaccination, we request that students provide proof of a negative COVID-19 test from the UW test site at the faculty lounge, dated within 24 hours of the study.

Study Design


Related Conditions & MeSH terms


Intervention

Behavioral:
virtual reality game
participants interact with a computer generated world

Locations

Country Name City State
United States University of Washington (only Psych students eligible, public not eligible for participation) Seattle Washington

Sponsors (1)

Lead Sponsor Collaborator
University of Washington

Country where clinical trial is conducted

United States, 

References & Publications (2)

Al-Ghamdi NA, Meyer WJ 3rd, Atzori B, Alhalabi W, Seibel CC, Ullman D, Hoffman HG. Virtual Reality Analgesia With Interactive Eye Tracking During Brief Thermal Pain Stimuli: A Randomized Controlled Trial (Crossover Design). Front Hum Neurosci. 2020 Jan 23;13:467. doi: 10.3389/fnhum.2019.00467. eCollection 2019. — View Citation

Hoffman HG. Interacting with virtual objects via embodied avatar hands reduces pain intensity and diverts attention. Sci Rep. 2021 May 21;11(1):10672. doi: 10.1038/s41598-021-89526-4. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Worst pain, baseline, participant's rating of "worst pain" during baseline measure Baseline, Worst pain rating using a single graphic rating scale, 0 = no pain, 10 = excruciating pain Immediately after a single 10 second test (no more than 10 minutes before the subsequent test stiim)
Primary participant's rating of "worst pain" during test phase Test phase, Worst pain rating using a single graphic rating scale, 0 = no pain, 10 = excruciating pain Immediately after each single 10 second test stimulus (< 10 minutes after baseline pain rating)
Secondary Baseline, participants rating of "time spent thinking about pain" Baseline Time thinking, Single a single graphic rating scale, 0 = none of the time, 10 = all of the time Immediately after a single 10 second test (no more than 10 minutes before the subsequent test stiim)
Secondary Test Phase, participants rating of "time spent thinking about pain" during test phase Test phase, Time rating, using a single graphic rating scale, 0 = none of the time, 10 = all of the time Immediately after each single 10 second test stimulus (< 10 minutes after baseline pain rating)
Secondary Baseline, participants rating of "pain unpleasantness" Baseline, Unpleasant rating, using single graphic rating scale, 0 = not unpleasant at all, 10 = excruciatingly unpleasant Immediately after a single 10 second test (no more than 10 minutes before the subsequent test stiim)
Secondary Test phase, participants rating of "pain unpleasantness" during test phase Test phase, pain unpleasantness, 0 = not unpleasant at all, 10 = excruciatingly unpleasant Immediately after each single 10 second test stimulus (< 10 minutes after baseline pain rating)
Secondary Baseline, participants rating of "Fun" during baseline Baseline fun, 0 = no fun at all, 10 = extremely fun Immediately after a single 10 second test (no more than 10 minutes before the subsequent test stiim)
Secondary Test Phase, participants ratings of "Fun" during test phase Test phase fun, 0 = no fun at all, 10 = extremely fun Immediately after each single 10 second test stimulus (< 10 minutes after baseline fun rating)
Secondary Baseline pain intensity: participants ratings of pain intensity during brief pair of 10 sec stimuli Baseline, pain intensity rating using a single graphic rating scale, 0 = no pain, 10 = excruciating pain Immediately after a single 10 second test (no more than 10 minutes before the subsequent test stiim)
Secondary Accuracy on the odd number task during No VR, Low tech VR and High tech VR participants accuracy on the attention demanding "odd number" task (Hoffman, 2021) No pain during this measure, measured within 10 minutes after the QST measures are completed.
See also
  Status Clinical Trial Phase
Completed NCT04356963 - Adjunct VR Pain Management in Acute Brain Injury N/A
Recruiting NCT06350084 - Effect of Mother's Touch and Nurse's Therapeutic Touch on Pain Level and Crying Time During Heel Blood Collection N/A
Completed NCT04080037 - Assessing Opioid Care Practices Using CPV Patient Simulation Modules N/A
Recruiting NCT05458037 - RCT of Pain Perception With Fast and Slow Tenaculum Application N/A
Completed NCT04571515 - Dose-Response Study of MR-107A-01 in The Treatment of Post-Surgical Dental Pain Phase 2
Recruiting NCT06005480 - Understanding Rebound Pain After Regional Anesthesia Resolution in Healthy Volunteers Phase 1
Active, not recruiting NCT04850079 - EHR Precision Drug Treatment in Neonates
Completed NCT03271151 - Effect of Duloxetine on Opioid Use After Total Knee Arthroplasty Phase 4
Completed NCT03272139 - Interscalene Block Versus Superior Trunk Block Phase 4
Recruiting NCT05383820 - Effect of Paracetamol and Ketorolac on RANK-L Levels in Patients Starting Orthodontic Treatment Phase 4
Completed NCT04851353 - Multiple Sensory Interventions On Infants' Pain and Physiological Distress During Neonatal Screening Procedures N/A
Completed NCT03280017 - Ketamine With Multilevel Paravertebral Block for Post Video-assisted Thoracic Surgery Pain Phase 4
Completed NCT04280796 - Changes in Affective Pain Processing in Human Volunteers N/A
Not yet recruiting NCT04523623 - Pain Control Differences Between Oxycodone and Ibuprofen in Children With Isolated Forearm Injuries N/A
Not yet recruiting NCT04491630 - COping With PAin Through Hypnosis, Mindfulness and Spirituality N/A
Not yet recruiting NCT04062513 - Olfactive Stimulation Interventions With Mothers' Milk on Preterm Pain Response N/A
Withdrawn NCT03137017 - A Comparison of Plasma Concentrations of Hydrocodone and Acetaminophen After Administration of a New and a Marketed Tablet Formulation Under Fasted and Fed Conditions in Healthy Adults Phase 1
Withdrawn NCT03137030 - A Comparison of Plasma Concentrations of Hydrocodone and Acetaminophen After Administration of Different Amounts of Tablets of a New and a Marketed Tablet Formulation in Healthy Adults Phase 1
Completed NCT04659395 - How to Develop a Training Program for Nurses in Ultrasound Guided Femoral Nerve Block N/A
Recruiting NCT03257319 - Inhaled vs IV Opioid Dosing for the Initial Treatment of Severe Acute Pain in the Emergency Department Phase 3